← Back to headlines
Corcept Projects $900M–$1B Revenue for 2026
Corcept has provided its revenue guidance for 2026, projecting between $900 million and $1 billion, as the approval for its relacorilant oncology drug approaches.
25 Feb, 00:48 — 25 Feb, 00:48
ℹOnly 1 source covers this story
